AKT1 and neoplasm: Multiple other studies have targeted PI3K, a kinase upstream of AKT, and demonstrated that PI3K blockade helped a variety of CAR T cells maintain a less differentiated phenotype with enhanced in vivo persistence and anti-tumor efficacy (52–57).